BCL2 and Miyoshi myopathy: BCL-XL and BCL-2 are known for their contribution to intrinsic apoptosis resistance in MM, and the BCL-2-targeting BH3-mimetic Venetoclax was shown to have clinical efficacy in RR-MM patients harboring a t(11;14) translocation [33].